voice searchcamera search
Daslemia 100mg Tablet

Daslemia 100mg Tablet

Price: 3673.95 INR / Bottle

(3499.00 INR + 5% GST)

Get Latest Price

MRP:

3673.95 INR / Piece

Weight :

60.00 Gram

1 Pack Contains :

30

Minimum Pack Size :

20

In Stock

In Stock

-20+

Product Specifications

Life SpanCheck expiry on pack
Origin of MedicineIndia
Pacakaging (Quantity Per Box)30 Tablets
Salt CompositionDasatinib 100 mg
Dosage FormTablet
IndicationChronic myeloid leukemia (CML), Philadelphia chromosome-positive
Packaging TypeBox
Drug TypeSpecific Drug
IngredientsDaslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).Daslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Physical FormTablets
FunctionOther
Recommended ForBlood cancer patients
DosageAs prescribed by physician
Dosage GuidelinesFollow medical advice
Suitable ForAdults
Quantity30 Tablets Boxes
Storage InstructionsStore in a cool, dry place
Supply Ability1000 Per Month
Delivery Time1 Week
Pkg Box Length11.50 cm
Packsize30
Weight60.00 Gram
Price Typefixed
Mop20
Price3499.00 INR (Approx.)
Shipping Typeactual
Pkg Box Height5.50 cm
ReturnableNo
GSTIN5%
CurrencyINR
Pkg Box Breadth6.00 cm
Unit TypePiece/Pieces
Stock Quantity1000000
MRP3673.95 INR
Brand NameDaslemia 100
Minimum Ordered Packs20

Company Details

Drugs and Devices is an entrepreneurial organization with its focus on domestic and global demand of healthcare requirement. This year we plan to launch our own products and will be ready to provide consultancy for 3rd Party / Contract manufacturing service to our International Clients. Also we are well versed with Export / Import procedure and are looking forward to serve globally.

Business Type

Exporter, Manufacturer, Service Provider, Distributor, Supplier, Trading Company, Wholesaler, Retailer, Dealer, Fabricator, Producer

Employee Count

5

Establishment

2019

Working Days

To

GST NO

24AAHCD5378G1ZJ

Payment Mode

Telegraphic Transfer (T/T)

Related Products

Explore Related Categories

More Products From This Seller

Industry Leader

Seller Details

GST

GST - 24AAHCD5378G1ZJ

4 RatingRating
Trusted SellerTrustedSeller
Super seller

Valsad, Gujarat

Seller Inquiry

Accepts only Foreign inquiries

Director

Mr F Shaikh

Members since

7 Years

Address

S-101, Drean Heights, Near Jama Masjid Dungra, Dungra Ct, Dungripada, Valsad, Gujarat, 396191, India

Report incorrect details

Compare With Similar Products

Buyer Feedback

4

4

Price Or Price Range

3499.0 INR (Approx.)

3095 INR (Approx.)

2630.0 INR (Approx.)

Minimum Order Quantity

5 Piece/Pieces

10 Bottle/Bottles

5 Box/Boxes

Life Span

Check expiry on pack

See expiry on pack

Origin Of Medicine

India

India

Pacakaging (Quantity Per Box)

30 Tablets

30 Tablets

Salt Composition

Dasatinib 100 mg

Dasatinib

Dosage Form

Tablet

Tablet

Indication

Chronic myeloid leukemia (CML), Philadelphia chromosome-positive

Chronic Myeloid Leukemia

Packaging Type

Box

Bottle

Drug Type

Specific Drug

Other Types

Other, Allopathic

Ingredients

Daslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).Daslemia 100 contains Dasatinib 100 mg, a potent targeted tyrosine kinase inhibitor produced by Intas Pharmaceuticals Ltd. It is widely prescribed for the management of Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Daslemia 100 acts by blocking targeted abnormal proteins that signal cancer cells to multiply. Manufactured in WHO-GMP compliant facilities, this product offers high bioequivalence and efficacy. Available in a pack of 30 tablets for international pharma distributors, hospital procurement, and wholesale export supply.Product Features:High efficacy oral targeted therapy formulation.Formulated in compliance with international quality and manufacturing standards.Moisture-sealed packaging to preserve stability and shelf-life.Manufactured by Intas Pharmaceuticals, a global healthcare leader.Applications:First-line treatment for adults with newly diagnosed chronic phase Ph+ CML.Treatment of post-imatinib resistant or intolerant Ph+ CML in adult patients.Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Dasatinib

Physical Form

Tablets

Tablets

Other, Tablet

Function

Other

Cancer Treatment

Anti-Cancer

Recommended For

Blood cancer patients

Anty cancer medicine

Chronic Myeloid Leukemia (CML)

Dosage

As prescribed by physician

50mg

100 mg

Dosage Guidelines

Follow medical advice

As prescribed by physician

Suitable For

Adults

Suitable For All

Adults

Quantity

30 Tablets Boxes

1

30 Tablets

Storage Instructions

Store in a cool, dry place

Store below 30C

Supply Ability

1000 Per Month

All time Per Day

500 Per Month

Delivery Time

1 Week

8 to 8. Hours

7 Days

People Also Viewed